Patents by Inventor John J. Nestor

John J. Nestor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide pharmaceuticals for insulin resistance
    Patent number: 11911447
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: February 27, 2024
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS
    Publication number: 20230218564
    Abstract: The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.
    Type: Application
    Filed: December 20, 2022
    Publication date: July 13, 2023
    Applicant: Mederis Diabetes LLC
    Inventor: John J Nestor
  • Peptide pharmaceuticals for treatment of NASH and other disorders
    Patent number: 11541028
    Abstract: The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: January 3, 2023
    Assignee: Altimmune Inc.
    Inventor: John J Nestor
  • PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
    Publication number: 20220362345
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: June 16, 2021
    Publication date: November 17, 2022
    Applicant: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • PEPTIDE PHARMACEUTICALS
    Publication number: 20220348611
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 3, 2022
    Inventor: John J. Nestor
  • GLP-1R and GCGR Agonists, Formulations, and Methods of Use
    Publication number: 20210290732
    Abstract: This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.
    Type: Application
    Filed: February 21, 2021
    Publication date: September 23, 2021
    Applicant: Spitfire Pharma LLC
    Inventors: John J Nestor, Vyjayanthi Krishnan
  • Peptide pharmaceuticals for insulin resistance
    Patent number: 11065304
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: July 20, 2021
    Assignee: Mederis Diabetes, LLC
    Inventor: John J. Nestor
  • IMPROVED PEPTIDE PHARMACEUTICALS
    Publication number: 20210077629
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: September 23, 2019
    Publication date: March 18, 2021
    Applicant: Mederis Diabetes LLC
    Inventor: John J. NESTOR
  • IMPROVED PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERS
    Publication number: 20200352900
    Abstract: The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for treating insulin resistance, diabetes, obesity, metabolic syndrome and cardiovascular diseases, and conditions associated therewith, such as NASH and PCOS.
    Type: Application
    Filed: January 3, 2019
    Publication date: November 12, 2020
    Applicant: Mederis Diabetes LLC
    Inventor: John J Nestor
  • IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
    Publication number: 20200289653
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: March 21, 2020
    Publication date: September 17, 2020
    Applicant: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
    Publication number: 20200277351
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: January 21, 2020
    Publication date: September 3, 2020
    Applicant: Mederis Diabetes LLC
    Inventor: John J. NESTOR
  • Peptide pharmaceuticals for insulin resistance
    Patent number: 10577405
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 3, 2020
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • Peptide pharmaceuticals for insulin resistance
    Patent number: 10471127
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: November 12, 2019
    Assignee: Mederis Diabetes, LLC
    Inventor: John J. Nestor
  • Peptide pharmaceuticals
    Patent number: 10420844
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 24, 2019
    Assignee: Mederis Diabetes LLC
    Inventor: John J. Nestor
  • PEPTIDE PHARMACEUTICALS
    Publication number: 20180327454
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: May 22, 2018
    Publication date: November 15, 2018
    Inventor: John J. Nestor
  • PEPTIDE PHARMACEUTICALS
    Publication number: 20180296681
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: March 6, 2018
    Publication date: October 18, 2018
    Inventor: John J. NESTOR
  • PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
    Publication number: 20180194826
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventor: John J. NESTOR
  • Peptide pharmaceuticals
    Patent number: 10010617
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: July 3, 2018
    Assignee: EUMEDERIS PHARMACEUTICALS, INC.
    Inventor: John J. Nestor
  • Peptide pharmaceuticals
    Patent number: 10005817
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 26, 2018
    Assignee: EUMEDERIS PHARMACEUTICALS, INC.
    Inventor: John J. Nestor
  • Peptide pharmaceuticals for insulin resistance
    Patent number: 9856306
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: January 2, 2018
    Assignee: SPITFIRE PHARMA, INC.
    Inventor: John J. Nestor